Compare SPOK & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPOK | CADL |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 578.8M |
| IPO Year | 2004 | 2021 |
| Metric | SPOK | CADL |
|---|---|---|
| Price | $10.95 | $8.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $14.00 | ★ $19.00 |
| AVG Volume (30 Days) | 157.0K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | 2.74 | ★ 58.62 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $139,708,000.00 | $125,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $122.44 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $9.95 | $4.35 |
| 52 Week High | $19.31 | $9.27 |
| Indicator | SPOK | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 58.29 |
| Support Level | $10.87 | $4.91 |
| Resistance Level | $11.55 | $9.27 |
| Average True Range (ATR) | 0.24 | 0.65 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 69.83 | 30.53 |
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.